



## Article

# Therapeutic Potential of Cannabinoid Profiles Identified in *Cannabis L.* Crops in Peru

Pedro Wong-Salgado <sup>1,2,3,\*</sup>, Fabiano Soares <sup>2,3,4</sup>, Jeel Moya-Salazar <sup>5,\*</sup>, José F. Ramírez-Méndez <sup>1,3</sup>, Marcia M. Moya-Salazar <sup>3,6</sup>, Alfonso Apesteigua <sup>7</sup> and Americo Castro <sup>2</sup>

<sup>1</sup> CANNAVITAL, Clínica Especializada en Terapias con Cannabinoides, Lima 15022, Peru; farmacia@cannavital.com.pe

<sup>2</sup> RENATU Research Group, Faculty of Pharmacy and Biochemistry, Universidad Nacional Mayor de San Marcos, Lima 15039, Peru; fabiano@reaja.com.br (F.S.); cecannabisperu@upch.pe (A.C.)

<sup>3</sup> Centro de Estudios del Cannabis del Perú, Lima 15022, Peru; marciamilagros21@gmail.com

<sup>4</sup> REAJA Laboratory, Curitiba 80045-180, Brazil

<sup>5</sup> Faculties of Health Science, Universidad Privada del Norte, Lima 15001, Peru

<sup>6</sup> Cannabis and Stone Unit, Nesh Hubbs, Lima 15001, Peru

<sup>7</sup> Centro de Información, Control Toxicológico y Apoyo a la Gestión Ambiental CICOTOX, Faculty of Pharmacy and Biochemistry, Universidad Nacional Mayor de San Marcos, Lima 15039, Peru; japestegui@unmsm.edu.pe

\* Correspondence: pedro.wong@unmsm.edu.pe (P.W.-S.); jeel.moya@upne.edu.pe (J.M.-S.)

**Abstract:** Cannabis is a plant that is cultivated worldwide, and its use is internationally regulated, but some countries have been regulating its medicinal, social, and industrial uses. This plant must have arrived in Peru during the Spanish conquest and remains widely cultivated illicitly or informally to this day. However, new regulations are currently being proposed to allow its legal commercialization for medicinal purposes. Cannabis contains specific metabolites known as cannabinoids, some of which have clinically demonstrated therapeutic effects. It is now possible to quantitatively measure the presence of these cannabinoids in dried inflorescences, thus allowing for description of the chemical profile or “chemotype” of cannabinoids in each sample. This study analyzed the chemotypes of eight samples of dried inflorescences from cannabis cultivars in four different regions of Peru, and based on the significant variation in the cannabinoid profiles, we suggest their therapeutic potential. The most important medical areas in which they could be used include the following: they can help manage chronic pain, they have antiemetic, anti-inflammatory, and antipruritic properties, are beneficial in treating duodenal ulcers, can be used in bronchodilators, in muscle relaxants, and in treating refractory epilepsy, have anxiolytic properties, reduce sebum, are effective on Methicillin-resistant *Staphylococcus aureus*, are proapoptotic in breast cancer, can be used to treat addiction and psychosis, and are effective on MRSA, in controlling psoriasis, and in treating glioblastoma, according to the properties of their concentrations of cannabidiol, cannabigerol, and  $\Delta^9$ -tetrahydrocannabinol, as reviewed in the literature. On the other hand, having obtained concentrations of THC, we were able to suggest the psychotropic capacity of said samples, one of which even fits within the legal category of “non-psychoactive cannabis” according to Peruvian regulations.

**Keywords:** medical cannabis; tetrahydrocannabinol; therapeutic potential; chemical profile; cannabinoids; inflorescences; Peru



**Citation:** Wong-Salgado, P.; Soares, F.; Moya-Salazar, J.; Ramírez-Méndez, J.F.; Moya-Salazar, M.M.; Apesteigua, A.; Castro, A. Therapeutic Potential of Cannabinoid Profiles Identified in *Cannabis L.* Crops in Peru. *Biomedicines* **2024**, *12*, 306. <https://doi.org/10.3390/biomedicines12020306>

Academic Editor: Wesley M. Raup-Konsavage

Received: 22 August 2023

Revised: 15 September 2023

Accepted: 18 September 2023

Published: 29 January 2024



**Copyright:** © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

## 1. Introduction

With the arrival of the Spanish conquerors in the southern part of the American continent in the 15th century, some important plant species were introduced. Cannabis is considered an introduced plant, and is a shrub with industrial value (in textiles and paper), nutritional value (in seeds), and medicinal value (in inflorescences). Cannabis is considered native to the Euro-Asian region and its use has been documented since the earliest Chinese medical references from approximately 5000 years ago [1].

Cannabis exclusively contains a large number of terpenophenolic compounds called “cannabinoids”, which act as partial agonists to specific receptors within the nervous and immune systems of humans, as well as other mammalian and vertebrate species [2]. Cannabinoids that have demonstrated conclusive clinical effectiveness are  $\Delta^9$ -tetrahydrocannabinol ( $\Delta^9$ -THC), which has analgesic, anti-inflammatory, and antiemetic effects that help with chemotherapy-induced nausea and vomiting and with the management of chronic pain and muscle spasticity caused by multiple sclerosis; and cannabidiol (CBD), which has attenuating effects on refractory epileptic syndromes in children, specifically Dravet and Lennox–Gastaut syndromes [3–5].

In the late 20th century, it was discovered that our bodies produce molecules derived from arachidonic acid that function as regulators in the nervous and immune systems, similar to what had been demonstrated with phytocannabinoids. These molecules were named endogenous cannabinoids or “endocannabinoids”, and together with the system of receptors distributed throughout the body and the enzymes that mediate their presence, they were called the “Endocannabinoid System” [6], more recently referred to as the “Endocannabinoidome” at a broader level [7]. This system plays a regulatory role in promoting homeostasis.

An important bibliographic reference that describes the therapeutic effects of the main metabolites found in cannabis is an American Herbal Pharmacopoeia 2014 review entitled “Cannabis Inflorescence” [8]. The information within the review includes nomenclature, constituents, identification, and analysis.

Since Canada passed medicinal regulations in 2001 and then allowed nonmedicinal use in 2018, several countries in the American continent have followed suit [9]. In some countries, regulations perform strict control over THC presence or content, such as in the Brazilian case, where pharmaceutical products derived from cannabis must not exceed 0.2% in weight [10], and the pharmaceutical industry must perform their manufacture. In other countries, regulations promote various pathways of access to patients, even personal cultivation, in addition to allowing pharmaceutical products to be available through conventional channels, as is the case in Argentina [11].

Peru has made significant progress with both approaches, as its regulations allow the use of THC without limits for prescription and artisanal production through patient associations and the pharmaceutical industry. Unfortunately, the application of these regulations is not efficient; after six years of regulation, the Peruvian market continues to rely on foreign raw materials at higher costs, maintaining limited access and availability to less than 30% of registered patients in Peru [12].

### *1.1. Regulation and Cannabis Cultivars in Peru*

The use of this plant was restricted in Peru with the publication of Decree Law No. 22095, the Law for the Repression of Illicit Drug Trafficking, in 1978 [13]. Subsequently, it was completely forbidden by the Supreme Decree DS 023-2001SA (Regulation of Narcotics and Psychotropics) issued by the Ministry of Health in 2001 [14]. However, cannabis is considered the most commonly used illegal “substance” or “drug”, and its use is likely increasing in line with the worldwide trend [15]; antidrug authorities report the lifetime prevalence in the population is 14.8 [16].

Extensive areas of the country with favorable geographical conditions for cannabis cultivation have been identified in the Peruvian highlands (Ancash, Huánuco, Junín, and Cajamarca) and on the coast (Lima and La Libertad). However, there have been no publications of reports about the characterization and identification of nationwide cannabis varieties or cultivars as have been performed in other countries [17–20]. These cannabis cultivars throughout Peru must be the result of the plant’s acclimatization to different geographical regions. The cultivars of cannabis could have been introduced with the arrival of the Spanish during the time of conquest and could have been maintained by farmers (before the prohibition) and “narcotraffickers” (after the prohibition). However, this process

has not been properly documented in Peru. Antidrug authorities have identified two kinds of local demand: (a) for recreational purposes, and (b) for medicinal purposes [21].

Therefore, considering the risk of losing relevant information about national cultivars as a result of the implementation of the current medicinal regulations, in which licensed producers will introduce foreign genetics due to these regulations, it is necessary to identify, characterize, and quantitatively analyze the cultivars found within the national territory.

### 1.2. Phytocannabinoids

The predominant phytocannabinoid in the cannabis plant is  $\Delta^9$ -THC, synthesized and elucidated (chemical structure) by Rafael Mechoulam in 1964 [22]. This molecule is the product of the decarboxylation of tetrahydrocannabinolic acid (THCA), a non-psychoactive metabolite that originates from the biosynthetic pathway of cannabigerolic acid (CBGA) by the action of the enzyme THCA synthase [16].  $\Delta^9$ -THC is known for its psychotropic, analgesic, antiemetic, orexigenic, and anti-inflammatory properties.  $\Delta^9$ -THC is a partial agonist of CB1 receptors, which are predominantly expressed in the central nervous system, and CB2 receptors, which are primarily located in cells with immunological functions. Its pharmacokinetics depend on the route of administration, with differentiation between the hepatic metabolic (oral), sublingual, dermic, and pulmonary routes. In 1985, Dronabinol (synthetic  $\Delta^9$ -THC) was approved by the United States Food and Drug Administration (FDA) for the oral management of chemotherapy-induced nausea and vomiting and anorexia in HIV patients [23].

CBD is another 21-carbon terpenophenolic compound that forms after the decarboxylation of its precursor, cannabidiolic acid (CBDA) [24]. It is one of the most abundant non-psychoactive cannabinoids in the cannabis plant. It acts as an agonist on TRPV1 and 5-HT1A receptors to enhance adenosine receptor signaling [25]. Its neuroprotective, antioxidant, antipsychotic, and anticonvulsant actions are among the most important effects observed. In June 2018, the FDA approved the first drug derived from the cannabis plant, called EPIDIOLEX® (Jazz Pharmaceuticals, Dublin, Ireland), an oral solution predominantly containing CBD [26]. Cannabigerol (CBG) is the nonacidic form of cannabigerolic acid (CBGA), considered a non-psychoactive phytocannabinoid that antagonizes the CB1 and CB2 cannabinoid receptors. It is an agonist of the alpha-2 adrenergic receptor and a moderate antagonist of the 5HT1A receptor. This compound can also antagonize transient receptor potential vanilloid (TRPV) receptors, stimulating TRPV1, TRPV2, TRPA1, TRPV3, and TRPV4 [27]. A list of therapeutic uses is shown in Figure 1.




Compound	Potential Therapeutic Uses
 <p><math>\Delta^9</math>-Tetrahydrocannabinol (<math>\Delta^9</math>-THC)</p>	<p><b>Main Psychotropic Cannabinoid</b></p> <p>Management of Chronic Pain in Adults (A0)</p> <p>Analgesic via CB1 and CB2 Receptor Agonism (A1)</p> <p>Antiemetic (A2); (A3); (A4)</p> <p>Anti-inflammatory, Antioxidant (A5)</p> <p>Antipruritic, Cholestatic Jaundice (A6)</p> <p>Beneficial in Duodenal Ulcers (A7); Bronchodilator (A8)</p> <p>Muscle Relaxant (A9)</p> <p>Reduces Symptoms of Alzheimer's (A10); (A11)</p>
 <p>Cannabidiol (CBD)</p>	<p><b>Non-Psychotropic Cannabinoid</b></p> <p>Refractory Epilepsy in Dravet and Lennox–Gastaut Syndromes (A12)</p> <p>Anandamide Reuptake Inhibitor (A13)</p> <p>Anticonvulsant (A14)</p> <p>Antiemetic (A15)</p> <p>Anti-Inflammatory (A16)</p>

Figure 1. Cont.

	<p>Antagonizes THC Effects in Humans (A17)          Antioxidant (A18)          Anxiolytic via 5HT1A Receptor Agonism (A19); (A20); (A21)          Reduces Sebum/Sebocyte Proliferation (A22)          Effective Against Methicillin-Resistant Staphylococcus aureus (MRSA) (A23)          Increases Adenosine A2A Signaling (A24)          Proapoptotic Against Breast Cancer Cell Lines (A25)          Treatment for Addiction (A26)          Treatment for Psychosis (A27)</p>
 <p>Cannabigerol (CBG)</p>	<p><b>Non-Psychotropic Cannabinoid</b></p> <p>Agonist of Anandamide Reuptake Inhibition (at Low Micromolar Range) (A28)          Analgesic by Blocking the <math>\alpha</math>-2 Adrenergic Pathway (A29)          Antifungal (A30)          Effective against Methicillin-Resistant Staphylococcus aureus (MRSA) (A23)          GABA Reuptake Inhibitor (A31)          Reduces Keratinocyte Proliferation in Psoriasis (A32)          Reduces Glioblastoma Cell Survival (A33)</p>

**Figure 1.** “Potential therapeutic uses of main cannabinoids” according to AHP 2014 monograph. The complete list of updated research on therapeutic potential can be found in Appendix A.

### 1.3. Cannabis Chemical Profiles or “Chemotypes”

Phytocannabinoids are metabolites exclusively found in cannabis, and some of their therapeutic effects are famous. However, only a few medical areas currently classify these effects as having “conclusive efficacy” in systematic reviews on conditions like chronic pain, nausea and vomiting, muscle spasticity, refractory epileptic syndromes, and anxiety [28], with the main responsible metabolites being  $\Delta$ 9-THC, CBD, and to a lesser extent CBG. Additionally, the presence of certain terpenes such as beta-caryophyllene, myrcene, limonene, terpinolene, alpha-pinene, and alpha-terpineol seems to contribute to the medicinal effects.

There is a wide variety of Cannabis cultivars distributed worldwide, and one of the most useful ways to classify them (especially for medicinal purposes) is by using the chemical profile or “chemotype” of their main cannabinoids and terpenes in the female inflorescences. It is then possible to infer the potential therapeutic effects of cannabis cultivar samples by determining their chemotype through quantitative cannabinoid analysis.

Since cannabis has not yet returned to the pharmacopeias of countries with strict health surveillance, it is necessary to consider herbal pharmacopeias as a reference for health use. One of the most notable is the American Herbal Pharmacopoeia FHA, which published a monograph on cannabis inflorescences in 2014 [8]. This document is also included in the “List of bibliographic references supporting the safety of use and traditional use of natural resources or their associations” of the Ministry of Health of Peru [29].

Reports on Peruvian cannabis cultivars have been conducted solely by the police for eradication purposes, and thus no quantitative chemical analyses have been performed. Therefore, it is important to conduct research that can identify and quantify the existing cultivars in the country.

In this study, we identified cannabis cultivars in four Peruvian regions (three in the highlands and one on the coast). Additionally, we quantified the cannabinoids of the collected samples by developing a gas chromatography technique in order to generate a prediction of therapeutic potential based on the cannabis monograph of FHA and an updated literature review with references of higher relevance in the field, carried out by the author.

## 2. Materials and Methods

### 2.1. Study Design and Settings

We designed an observational study based on the analysis of the cultivars following the recommendations of the STROBE guidelines [30]. Peru is a South American country with approximately 33 million inhabitants and has three natural regions (coast, highlands, and jungle) with extensive diversity in flora and fauna. Geographic data are shown in Table 1. The collection of species and chemotype analysis were carried out with cannabis samples from four regions of Peru (Ayacucho and Cajamarca, located geographically in the highlands), and the study was conducted during the second half of 2021.


**Table 1.** Baseline geographic characteristics of Peruvian sampling zones.

Region	M.A.S.L.	Climate	Average Humidity (%)	Average Temperature °C/F
Lima	200	Arid subtropical	80	17.4 (63.3)
Ayacucho	2760	Inter-Andean valley	56	17.5 (63.5)
Trujillo	34	Arid subtropical	89	19.7 (67.46)
Cajamarca	2750	Inter-Andean valley	72	13 (55.4)

### 2.2. Crop and Cannabinoid Identification

#### 2.2.1. Crops and Inclusion Criteria

In each region (Figure 2), inflorescence samples were collected (a total of 8 samples) from adult horticulturists and farmers who conserve “local varieties” and, although these producers allowed the sampling procedure, they refrained from providing extra data due to the risks concerning legal interpretation of cannabis cultivation without commercial purposes (trafficking).




**Figure 2.** Sampling zones of cannabis cultivars in Peru. The cannabinoid concentration of each sample is shown by region in the coast and highlands. Created using ARGics v13.4. Abbreviations: THC: Δ9-tetrahydrocannabinol, CBD: cannabidiol, CBG: cannabigerol.

We included Peruvian crops from willing local producers in Peru. These crops comprised “local varieties”, untainted by illicit trafficking or trade, and were accessible for research on cannabis plants throughout the year 2021. Fresh inflorescences were obtained from each cultivar, and in one case, a complete plant was allowed to be collected by using simple traction [31]. Before each sampling, a survey of the cultivation area was conducted to include plants over 1 m in size that were in the flowering stage and ready for harvest. We performed a simple random sampling and included unfertilized female cannabis plants in the flowering stage (without seeds).

### 2.2.2. Botanical Characterization and Cannabinoid Quantification

The collected inflorescence samples were stored and transported from the sampling zones in each region to the Faculty of Pharmacy and Biochemistry of the Universidad Nacional Mayor de San Marcos (UNMSM) in Lima. Additionally, the only sample of a complete plant was sent to the Museum of Natural History of UNMSM. The samples were identified as *Cannabis L.*, and the inflorescences were dried following a previous protocol [32]. The experimental methodology for obtaining standardized extracts is shown in Figure 3. We used 130 mg of dried cannabis inflorescences from each cultivar for chromatographic analysis, following international recommendations [33].



**Figure 3.** Experimental analysis for the quantification of cannabinoids in dried cannabis inflorescences obtained from cultivars in four regions of Peru.

The equipment used was a gas chromatograph coupled with a flame ionization detector (FID), model 7890A (Agilent, Santa Clara, CA, USA), using a fused silica capillary rtx-5MS column with dimensions 30 m × 0.25 mm × 0.25 mm and helium as the carrier gas, with an 18 min analysis time [34]. Quantitative chemical analysis was performed for the main secondary metabolites (THC, CBD, CBG, and CBN), for which imported standards

were available. Official cannabis sample identification and cannabinoid quantification had never been performed in Peru before this study (Certificate of Registration of the Museum of Natural History N°012-USM-2020).

### 2.2.3. Potential Therapeutic Profiles


The chemotypes of cannabinoids found in each sample of cannabis inflorescences were related to the therapeutic effects described for each cannabinoid in the FHA monograph [8]. In this way, potential therapeutic effects were proposed for each of the eight cannabis samples based on the concentrations of THC, CBD, CBG, and cannabinol (CBN) (a “by-product” cannabinoid resulting from the degradation of THC).

### 2.3. Data Analysis

We used IBM SPSS v22.0 software (Armonk, NY, USA) for Windows (California, US). Continuous variables were shown as means with standard deviation, and categorical variables were shown as frequencies. The concentration of cannabinoids was presented according to the sampling zone in each Peruvian region. The concentration was presented as mean and standard deviation, and a 95% confidence interval (CI) was used.

## 3. Results

A total of eight samples were analyzed in 28 chromatographic assays. One sample was collected in the region of Cajamarca (F1), and three samples were from Lima (F2–F4), while Trujillo (F5–F6) and Ayacucho (F7–F8) each had two samples from their regions. The average concentrations of CBG, CBD, and THC were  $1.52 \pm 0.21$  (CI 95%, 1.28 to 1.75),  $1.20 \pm 0.57$  (CI 95%, 0.56 to 1.84), and  $6.83 \pm 3.81$  (CI 95%, 4.19 to 9.47), respectively (Figure 4). The distribution of cannabis samples found in Peru is shown in Figure 2.



**Figure 4.** Cannabinoid profiles identified in cannabis crops in Peru. The pink dot are the samples analyzed. Abbreviations: THC:  $\Delta^9$ -tetrahydrocannabinol, CBD: cannabidiol, CBG: cannabigerol.

Table 2 shows the potential therapeutic uses of the collected samples according to the FHA 2014 monograph and the updates to it made by the author, shown in Figure 1. Most of the cannabis samples had high concentrations of THC; only one sample had less than one percent. Three samples contained CBG in low concentrations, less than 2 percent, and only two species from Lima and one from Cajamarca contained CBD, but in low concentrations.

Regarding psychotropic effects, three of the samples could have large psychotropic effects, three samples could have moderate effects, one sample could have a very small effect, and one sample would have a null psychotropic effect.

**Table 2.** Potential uses and therapeutic effects of cannabinoids according to the Peruvian geographical region. (Figure 1).

Sample	Region of Origin	Geographical Region	Cannabinoid Profile	Potential Therapeutic Effect
F1	Cajamarca	Highlands	THC: 2.24% CBD: 0.81% CBG: ND	<p>Potency of effect: Low.</p> <p>Medical areas of potential: Chronic pain management, antiemetic use, anti-inflammatory use, antipruritic use, duodenal ulcer treatment, bronchodilators, muscle relaxants, and treating Alzheimer’s disease symptoms due to the presence of THC. Refractory epilepsy treatment, anxiolytic use, sebum reduction, proapoptotic use in breast cancer, and are effective on MRSA and in addiction and psychosis treatments due to the presence of CBD.</p> <p>Psychotropic effect: Very small.</p>
F2	Lima	Coast	THC: 13.21% CBD: ND CBG: 1.45%	<p>Potency of effect: Very high.</p> <p>Medical areas of potential: Chronic pain management, antiemetic use, anti-inflammatory use, antipruritic use, duodenal ulcer treatment, bronchodilators, muscle relaxants, and treating Alzheimer’s disease symptoms due to the presence of THC in high amounts; effective on MRSA, in controlling psoriasis, and in glioblastoma treatment due to the presence of CBG.</p> <p>Psychotropic effect: Large.</p>
F3	Lima	Coast	THC: 9.80% CBD: 0.79% CBG: ND	<p>Potency of effect: High.</p> <p>Medical areas of potential: Chronic pain management, antiemetic use, anti-inflammatory use, antipruritic use, duodenal ulcer treatment, bronchodilators, muscle relaxants, and treating Alzheimer’s disease symptoms due to the presence of THC. Refractory epilepsy treatment, anxiolytic use, sebum reduction, proapoptotic in breast cancer, and are effective on MRSA and in addiction and psychosis treatments due to the presence of CBD.</p> <p>Psychotropic effect: Moderate.</p>
F4	Lima	Coast	THC: 0.78% CBD: 2.0% CBG: ND	<p>Potency of effect: Moderate.</p> <p>Medical areas of potential: Chronic pain management, antiemetic use, anti-inflammatory use, antipruritic use, duodenal ulcer treatment, bronchodilators, muscle relaxants, and treating Alzheimer’s disease symptoms due to the presence of THC. Refractory epilepsy treatment, anxiolytic use, sebum reduction, proapoptotic in breast cancer, and are effective on MRSA and in addiction, and psychosis treatments due to the presence of CBD.</p> <p>Psychotropic effect: Null.</p>



Table 2. Cont.

Sample	Region of Origin	Geographical Region	Cannabinoid Profile	Potential Therapeutic Effect
F5	La Libertad	Highlands	THC: 8.1% CBD: ND CBG: 1.30%	Potency of effect: High. Medical areas of potential: Chronic pain management, antiemetic use, anti-inflammatory use, antipruritic use, duodenal ulcer treatment, bronchodilators, muscle relaxants, and treating Alzheimer's disease symptoms due to the presence of THC in high amounts; effective on MRSA, in controlling psoriasis, and in glioblastoma treatments due to the presence of CBG. Psychotropic effect: Large.
F6	La Libertad	Highlands	THC: 9.06% CBD: ND CBG: 1.83%	Potency of effect: High. Medical areas of potential: Chronic pain management, antiemetic use, anti-inflammatory use, antipruritic use, duodenal ulcer treatment, bronchodilators, muscle relaxants, and treating Alzheimer's disease symptoms due to the presence of THC in high amounts; effective on MRSA, in controlling psoriasis, and in glioblastoma treatments due to the presence of CBG. Psychotropic effect: Large.
F7	Ayacucho	Highlands	THC: 5.93% CBD: ND CBG: ND	Potency of effect: Moderate. Medical areas of potential: Chronic pain management, antiemetic use, anti-inflammatory use, antipruritic use, duodenal ulcer treatment, bronchodilators, muscle relaxants, and treating Alzheimer's disease symptoms due to the presence of THC; small psychotropic effect. Psychotropic effect: Moderate.
F8	Ayacucho	Highlands	THC: 5.45% CBD: ND CBG: ND	Potency of effect: Moderate. Medical areas of potential: Chronic pain management, antiemetic use, anti-inflammatory use, antipruritic use, duodenal ulcer treatment, bronchodilators, muscle relaxants, and treating Alzheimer's disease symptoms due to the presence of THC; small psychotropic effect. Psychotropic effect: Moderate.

#### 4. Discussion

Peru is a country with an ancestral tradition of using phytotherapy, and the population normally uses medicinal plants concomitantly with their medical treatments; this could explain the rapid acceptance of the use of cannabis for medicinal therapy. Although regulation is not completely effective and the possibility of obtaining cannabis and derivatives in pharmacies is still limited, the population considers the use of this plant legitimate, and people decide to use it outside the health system. All this converges in the fact that 70% of the population of cannabis user patients continues acquiring artisanal products [35], which come mainly from national cannabis cultivars. Before the approval of the regulation of the medicinal use of cannabis in Peru, the focus of scientific studies regarding the use of cannabis was generally limited to its harms in terms of mental health, and this paradigm remains solid in many sectors; thus, studies like this could open the way to generating knowledge and interest in botanical collection, identification, analysis of chemical characteristics, and studies of the therapeutic use of a plant of high medicinal value that, outside of its legal status, is present in Peruvian territory [36]. Talking about the potential therapeutic

effects of Peruvian cannabis cultivars intended for nonmedicinal use or adult use invites us to reflect on whether this use means harm in all cases; if there is an underdiagnosed population of patients who find in cannabis an improvement in their quality of life; or if the incineration of all informal/illegal crops by the authorities is efficient and ecological. Perhaps we can respond to these facts in a different way, based on new scientific findings, with more flexible cannabis control regulations for patients and more appropriate policies for the use of resources from agriculture, in a country that needs improvements in these three aspects.

Future studies with a larger number of samples, representing all 24 departments of Peru within the three main regions (coast, highlands, and jungle), and using registered genetics, are necessary to explore the relationships between this plant, its environmental conditions, and the therapeutic effects it exhibits. Additionally, there is a risk of losing information about cannabis cultivars adapted to Peruvian geography, information which could be advantageous in light of the arrival of foreign varieties during the upcoming period of national production implementation for medicinal and industrial cannabis derivatives.

#### 4.1. Strengths

This study is the first study in Peru that involved (i) collecting cannabis samples from different regions, (ii) performing an official botanical identification, and (iii) developing and performing a technique for cannabinoid quantification. Due to the increasing interest in the medicinal use of cannabis in Peru, it is now possible to study the plant from a different perspective, focusing on potential therapeutic benefits rather than health risks [21,34]. Another strength lies in the description of potential therapeutic uses of the cultivars found in different geographical regions, which could guide researchers in further investigations in this area, patients in the knowledge of the products are using, and producers in the future industrialization of cannabis or cannabinoid production for medicinal purposes, taking advantage of the adapted chemotypes that possibly develop in each region of the country.

#### 4.2. Main Findings

In the four regions of Peru, there were national cannabis cultivars prior to the implementation of medicinal regulation. This regulation in theory allows the cultivation and production of cannabis derivatives; however, cannabis user patients have, until now, been supplied with imported raw materials and artisanal products from informal national cultivars [37]. Although various research laboratories in universities, industries, and police departments have liquid and gas chromatography equipment, as of the time of this study, there is no published evidence of analytical methodologies to quantify cannabinoids, making it impossible to carry out agricultural and biomedical research or quality control services.

All cannabis chemotypes found in this study have detectable concentrations of THC, and in the majority of samples this concentration is high. This could be because the informal/illegal cannabis market in Peru has historically been intended for nonmedicinal use (or adult use) in which the psychotropic effect is valued; fortunately, THC is also the molecule that has the most evidence for its usefulness in the most common medical areas among patients seeking treatment with cannabis, such as in the areas of chronic pain management, antiemetic treatment, or anti-inflammatory treatment, among others. On the other hand, three of the eight samples have detectable concentrations of CBD; one of these samples (F4) has double the concentration of CBD over THC, making it potentially useful for cases of refractory epilepsy, which is why these nonmedicinal-purpose cannabis cultivars have been appreciated by the more than 40 thousand patients registered to date in the country. However, it is necessary to complement these studies with quality controls to avoid bacterial infections, pesticide poisoning, and heavy metal poisoning.

Sample collection was constrained to regions where limited permissibility for gathering could be obtained, due to the stigma associated with cannabis cultivation, which is often linked with illicit drug trafficking. The collection phase spanned four months, and the

volume of samples and the number of regions were both relatively modest. In this study, samples were only accessible from 4 out of the 24 regions in Peru. Furthermore, this research marked the inaugural instance of the chromatographic quantification of cannabinoids in Peru. Procuring cannabinoid standards from international sources incurred significant expenses, necessitating a more extensive array of standards to yield more detailed findings. Additionally, the outcomes are presented in terms of total THC and total CBD. This was due to the limitations of the available equipment for this investigation, which employed a gas chromatograph. The injection temperature for this equipment exceeded the decarboxylation temperature of the cannabinoids, rendering it challenging to identify and quantify acidic cannabinoids. Consequently, this study focused on the overall concentrations of THC and CBD as opposed to individual cannabinoid variants.

## 5. Conclusions

Cannabis cultivars, that existed before Peruvian medicinal regulation, have potential therapeutic effects. Due to the variety in cannabinoid chemotypes found in cannabis samples from four different regions, these potential therapeutic effects can vary according to the concentrations of the cannabinoids that show major evidence of therapeutic effects, like THC, CBD, and CBG. The most important effects include the following: managing chronic pain, antiemetic, anti-inflammatory, and antipruritic effects, beneficial effects in treating duodenal ulcers, use in bronchodilators, use as a muscle relaxant, treating refractory epilepsy, anxiolytic effects, sebum reduction, effectiveness on MRSA, proapoptotic effects in breast cancer, and effectiveness in addiction and psychosis treatments, as well as effectiveness in controlling psoriasis and in treating glioblastoma. This potential invites us to continue botanical collection and select interesting chemotypes in agronomic studies with a view to proposing biomedical, observational, or clinical research.

On the other hand, having obtained concentrations of THC, we were able to propose a simple scale of the psychotropic capacity of said samples. Seven samples have psychotropic effects, and one of them fits within the legal category of “non-psychoactive cannabis”, which represents less than one percent according to Peruvian regulations. This information could be useful for patients and health professionals, since the majority of the population of Peruvians who use cannabis for medicinal purposes is supplied by the illegal/informal cannabis market. The conservation of these cultivars could be necessary in anticipation of the arrival of foreign genetics during the upcoming period of medicinal and industrial cannabis regulation implementation. Additionally, completing a catalogue of national cultivars and eventually exploring causal relationships between cannabis plant cannabinoid proportions and the environmental conditions of the region of origin are essential. It is possible and necessary to continue chemically, morphologically, and genetically identifying and quantifying cultivars from other regions of Peru, as well as developing and implementing more chromatographic techniques for cannabinoid quantification in universities, research institutes, and public and private quality control laboratories in response to the needs of patients, health care professionals, researchers, and companies dedicated to this field, as these services are currently not available.

**Author Contributions:** Conceptualization, P.W.-S. and F.S.; methodology, P.W.-S.; software, J.F.R.-M. and A.A.; validation, P.W.-S., F.S. and M.M.M.-S.; formal analysis, J.M.-S.; investigation, P.W.-S.; resources, P.W.-S. and A.C.; data curation, J.M.-S.; writing—original draft preparation, P.W.-S., F.S., J.F.R.-M. and A.C.; writing—review and editing, P.W.-S., J.M.-S. and M.M.M.-S.; visualization, J.M.-S.; supervision, J.F.R.-M.; project administration, P.W.-S. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Institutional Review Board Statement:** This study was conducted in accordance with the Declaration of Helsinki, and approved by the Ethics Committee of the Universidad Nacional Mayor de San Marcos (protocol code 200-145-21).

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** Data will be disclosed upon request to the authors.

**Acknowledgments:** We thank all the crop owners for providing us with access to samples for collection. We also want to thank Carla Del Carpio from Universidad Nacional San Antonio Abad of Cuzco (Peru) and Emilio Ramírez from Universidad Nacional San Cristobal de Huamanga of Ayacucho (Peru) for their support in the analysis of the samples. Finally, we would like to thank Claudio García from the University of Temuco (Chile) for his support in the preparation of the maps.

**Conflicts of Interest:** The authors declare no conflict of interest.

## Appendix A

- A0. National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Population Health and Public Health Practice; Committee on the Health Effects of Marijuana: An Evidence Review and Research Agenda. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Washington (DC): National Academies Press (US); 2017 Jan 12. 2, Cannabis.
- A1. Rahn EJ, Hohmann AG. 2009. Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside. *Neurotherapeutics* 6:713-37.
- A2. Haney M, Gunderson EW, Rabkin J, Hart CL, Vosburg SK, Comer SD, Foltin RW. 2007. Dronabinol and marijuana in HIV-positive marijuana smokers. Caloric intake, mood and sleep. *JAIDS* 45:545-54.
- A3. Hollister LE. 1971. Hunger and appetite after single doses of marihuana, alcohol, and dextroamphetamine. *Clin Pharmacol Ther* 12:44-9.
- A4. Machado Rocha FC, Stefano SC, De Cassia Haiek R, Rosa Oliveira LM, Da Silveira DX. 2008. Therapeutic use of Cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis. *Eur J Can Care* 17:431-43.
- A5. Hampson AJ, Grimaldi M, Axelrod J, Wink D. 1998. Cannabidiol and (-)- $\Delta^9$ -tetrahydrocannabinol are neuroprotective antioxidants. *Proc Natl Acad Sci* 95:8268-73.
- A6. Neff GW, O'Brien CB, Reddy KR, Bergasa NV, Regev A, Molina E, Amaro R, Rodriguez MJ, Chase V, Jeffers L. et al. 2002. Preliminary observation with dronabinol in patients with intractable pruritus secondary to cholestatic liver disease. *Am J Gastroenterol* 97:2117-9.
- A7. Douwaite AH. 1947. Choice of drugs in the treatment of duodenal ulcer. *BMJ* 2:43-7.
- A8. Williams SJ, Hartley JPR, Graham JDP. 1976. Bronchodilator effect of  $\Delta^1$ -tetrahydrocannabinol administered by aerosol to asthmatic patients. *Thorax* 31:720-3.
- A9. Kavia R, De Ridder D, Constantinescu CS, Stott CG, Fowler CJ. 2010. Randomised controlled trial of Sativex to treat detrusor over activity in multiple sclerosis. *Mult Scler* 16:1349-59.
- A10. Eubanks LM, Rogers CJ, Beuschner AE, Koob GF, Dickerson TJ, Janda KD. 2006. A molecular link between the active component of marijuana and Alzheimer's disease pathology. *Mol Pharmacol* 3:773-7.
- A11. Volicer L, Stelly M, Morris J, McLaughlin J, Volicer BJ. 1997. Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease. *Int J Geriatr Psychiatry* 12(9):913-9.
- A12. EPIDIOLEX® USPI. Highlights of prescribing information: EPIDIOLEX® (cannabidiol) oral solution. HYPERLINK "sps:urlprefix::https" [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2020/210365s005s006s0071bl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210365s005s006s0071bl.pdf). Accessed October 28, 2020.
- A13. De Petrocellis L, Ligresti A, Moriello AS, Allara M, Bisogno T, Petrosino S, Stott CG, Di Marzo V. 2011a. Effects of cannabinoids and cannabinoid-enriched cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. *Br J Pharmacol* 163:479-94.
- A14. Jones NA, Hill AJ, Smith I, Bevan SA, Williams CM, Whalley BJ, Stephens GJ. 2010. Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo. *J Pharmacol Exp Ther* 332:569-77.
- A15. Rock EM, Goodwin JM, Limebeer CL, Breuer A, Pertwee RG, Mechoulam R, Parker LA. 2010. Interaction between non-psychotropic cannabinoids in marijuana: effect of cannabigerol (CBG) on the anti-nausea or anti-emetic effects of cannabidiol (CBD) in rats and shrews. *Psychopharmacology* 215:505-12.
- A16. Booz GW. 2011. Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress. *Free Rad Biol Med* 51:1054-61.
- A17. Pertwee RG. 2008. The diverse CB<sub>1</sub> and CB<sub>2</sub> receptor pharmacology of three plant cannabinoids:  $\Delta^9$ -tetrahydrocannabinol, cannabidiol and  $\Delta^9$ -tetrahydrocannabivarin. *Br J Pharmacol* 153:199-215.

**Figure A1.** Cont.

- A18. Hampson AJ, Grimaldi M, Axelrod J, Wink D. 1998. Cannabidiol and (-) $\Delta$ -tetrahydrocannabinol are neuroprotective antioxidants. *Proc Natl Acad Sci* 95:8268-73.
- A19. Campos AC, Guimaraes FS. 2008. Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats. *Psychopharmacology* 199:233-30.
- A20. Resstel LB, Tavares RF, Lisboa SF, Joca SR, Correa FM, Guimaraes FS. 2009. 5HT1A receptors are involved in the cannabidiol-induced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats. *Br J Pharmacol* 156:181-8.
- A21. Russo EB, Burnett A, Hall B, Parker KK. 2005. Agonistic properties of cannabidiol at 5-HT1a receptors. *Neurochem Res* 30:1037-43.
- A22. Biro T, Toth BI, Hasko G, Paus R, Pacher P. 2009. The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities. *Trends Pharmacol Sci* 30:411-20.
- A23. Appendino G, Gibbons S, Giana A, Pagani A, Grassi G, Stavri M, Smith E, Rahman MM. 2008. Antibacterial cannabinoids from *Cannabis sativa*: a structure-activity study. *J Nat Prod* 71:1427-30.
- A24. Carrier EJ, Auchampach JA, Hillard CJ. 2006. Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression. *Proc Natl Acad Sci USA* 103:7895-900.
- A25. Ligresti A, Moriello AS, Starowicz K, Matias I, Pisanti S, De Petrocellis L, Laezza C, Portella G, Bifulco M, Di Marzo V. 2006. Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. *J Pharmacol Exp Ther* 318:1375-87.
- A26. Xi ZX, Peng XQ, Li X, Zhang H, Li JG, Gardner EL. 2010. Brain cannabinoid CB2 receptors inhibit cocaine self-administration and cocaine-enhanced extracellular dopamine in mice. *Proceedings 20th Annual Symposium on the Cannabinoids*. Lund: International Cannabinoid Research Society. P. 32.
- A27. Russo EB, Guy GW, Robson PJ. 2007. Cannabis, pain, and sleep; lessons from therapeutic clinical trials of sativex, a cannabis-based medicine. *Chem Biodiver* 4:1729-43.
- A28. De Petrocellis L, Vellani V, Schiano-Moriello A, Marini P, Magherini PC, Orlando P, Di Marzo V. 2008. Plant-derived cannabinoids modulate the activity of transient receptor potential channels of ankyrin type-1 and melastatin type-8. *J Pharmacol Exp Ther* 325:1007-15.
- A29. Cascio MG, Gauson LA, Stevenson LA, Ross R, Pertwee RG. 2010. Evidence that the plant cannabinoid cannabigerol is highly potent  $\alpha$ 2-adrenoceptor agonist and moderately potent 5HT1A receptor antagonist. *Br J Pharmacol* 159:129-41.
- A30. Elsohly HN, Turner CE, Clark AM, Elsohly MA. 1982. Synthesis and antimicrobial activities of certain cannabichromene and cannabigerol related compounds. *J Pharm Sci* 71:319-23.
- A31. Banerjee SP, Snyder SH, Mechoulam R. 1975. Cannabinoids: influence on neurotransmitter uptake in rat brain synaptosomes. *J Pharmacol Exp Ther* 194:74-81.
- A32. Wilkinson JD, Williamson EM. 2007. Cannabinoids inhibit human keratinocyte proliferation through a non-CB<sub>1</sub>/CB<sub>2</sub> mechanism and have a potential therapeutic value in the treatment of psoriasis. *J Dermatol Sci* 45:87-92.
- A33. Lah T., Novak M., Almidon M., Marinelli O., Baškovič B., Majc B., Mlinar M., Bošnjak R., Breznik B., Zomer R., et al. Cannabigerol Is a Potential Therapeutic Agent in a Novel Combined Therapy for Glioblastoma. *Cells*. 2021;10:340.

**Figure A1.** Reference list for updating information on the therapeutic potential of cannabinoids according to FHA 2014.

## References

1. Pain, S. A potted history. *Nature* **2015**, *525*, S10–S11. [[CrossRef](#)] [[PubMed](#)]
2. Long, T.; Wagner, M.; Demske, D.; Leipe, C.; Tarasov, P.E. Cannabis in Eurasia: Origin of human use and Bronze Age trans-continental connections. *Veg. Hist. Archaeobot.* **2017**, *26*, 245–258. [[CrossRef](#)]
3. Maccarrone, M. *Endocannabinoid Signaling: Methods and Protocols*, 2nd ed.; Humana Press: London, UK, 2022.
4. Whiting, P.F.; Wolff, R.F.; Deshpande, S.; Di Nisio, M.; Duffy, S.; Hernandez, A.V.; Keurentjes, J.C.; Lang, S.; Misso, K.; Ryder, S.; et al. Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. *JAMA* **2015**, *313*, 2456–2473. [[CrossRef](#)] [[PubMed](#)]
5. Connor, J.P.; Stjepanović, D.; Le Foll, B.; Hoch, E.; Budney, A.J.; Hall, W.D. Cannabis use and cannabis use disorder. *Nat. Rev. Dis. Primers* **2021**, *7*, 16. [[CrossRef](#)] [[PubMed](#)]
6. Levine, J. *Understanding Medical Cannabis: Critical Issues and Perspectives for Human Service Professionals*; Routledge: London, UK, 2020.
7. Di Marzo, V.; Wang, J. *The Endocannabinoidome: The World of Endocannabinoids and Related Mediators*; Academic Press: London, UK, 2021.

8. Devinsky, O.; Cross, J.H.; Laux, L.; Marsh, E.; Miller, I.; Nabbout, R.; Scheffer, I.E.; Thiele, E.A.; Wright, S. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. *N. Engl. J. Med.* **2017**, *376*, 2011–2020. [[CrossRef](#)] [[PubMed](#)]
9. Bonnett, M. Historical Overview on the Evolution and Legislation of Cannabis in Latin America. Meritas. Available online: <https://www.meritas.org/insight/article/Historical-Overview-on-the-evolution-and-legislation-of-cannabis-in-latin-america> (accessed on 16 August 2023).
10. Ministério da Saúde. Resolução da Diretoria Colegiada—RDC N° 327. Available online: <https://www.in.gov.br/en/web/dou/-/resolucao-da-diretoria-colegiada-rdc-n-327-de-9-de-dezembro-de-2019-232669072> (accessed on 16 August 2023).
11. Ministerio de Salud. LEY N° 27.350 Investigacion Medica y Cientifica de Uso Medicinal de la Planta de Cannabis y Sus Derivados. Available online: <https://www.argentina.gob.ar/normativa/nacional/ley-27350-273801/normas-modifican> (accessed on 16 August 2023).
12. La República. Reglamento del Minsa No Beneficia a los Usuarios del Cannabis Medicinal. Available online: <https://larepublica.pe/sociedad/2023/03/10/reglamento-del-minsa-no-beneficia-a-los-usuarios-del-cannabis-medicinal-489440> (accessed on 16 August 2023).
13. Ministerio del Interior. LEY No 22095 Ley de Represión de Tráfico Ilícito de Drogas. Available online: <https://www.gob.pe/institucion/corahperu/normas-legales/850797-22095> (accessed on 16 August 2023).
14. Ministerio de Salud. DS 023—2001SA Reglamento de Estupefacientes y Psicotrópicos. Available online: <https://www.gob.pe/institucion/minsa/normas-legales/255646-023-2001-sa> (accessed on 16 August 2023).
15. Comisión Nacional para el Desarrollo y Vida sin Droga. *Politica Nacional Contra las Drogas al 2030*; DEVIDA: Lima, Peru, 2022.
16. ElSohly, M.A.; Slade, D. Chemical constituents of marijuana: The complex mixture of natural cannabinoids. *Life Sci.* **2005**, *78*, 539–548. [[CrossRef](#)] [[PubMed](#)]
17. Cicaloni, V.; Salvini, L.; Vitalini, S.; Garzoli, S. Chemical Profiling and Characterization of Different Cultivars of *Cannabis sativa* L. Inflorescences by SPME-GC-MS and UPLC-MS. *Separations* **2022**, *9*, 90. [[CrossRef](#)]
18. Murovec, J.; Eržen, J.J.; Flajšman, M.; Vodnik, D. Analysis of Morphological Traits, Cannabinoid Profiles, THCAS Gene Sequences, and Photosynthesis in Wide and Narrow Leaflet High-Cannabidiol Breeding Populations of Medical Cannabis. *Front. Plant Sci.* **2022**, *13*, 786161. [[CrossRef](#)] [[PubMed](#)]
19. Tipparat, P.; Natakankitkul, S.; Chamnivikaipong, P.; Chutiwat, S. Characteristics of cannabinoids composition of Cannabis plants grown in Northern Thailand and its forensic application. *Forensic Sci. Int.* **2012**, *215*, 164–170. [[CrossRef](#)] [[PubMed](#)]
20. San Nicolas, M.; Villate, A.; Gallastegi, M.; Aizpurua-Olaizola, O.; Olivares, M.; Etxebarria, N.; Usobiaga, A. Chapter Three—Analysis of cannabinoids in plants, marijuana products and biological tissues. *Compreh. Anal. Chem.* **2020**, *90*, 65–102. [[CrossRef](#)]
21. National Academies of Sciences, Engineering, and Medicine. Health and Medicine Division; Board on Population Health and Public Health Practice; Committee on the Health Effects of Marijuana: An Evidence Review and Research Agenda. In *The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research*; National Academies Press: Washington, DC, USA, 2017.
22. Gaoni, Y.; Mechoulam, R. Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish. *J. Am. Chem. Soc.* **1964**, *86*, 1646–1647. [[CrossRef](#)]
23. Food and Drug Administration. MARINOL (Dronabinol) Capsules, for Oral Use. Available online: [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2017/018651s029lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018651s029lbl.pdf) (accessed on 16 August 2023).
24. Meccariello, R.; Chianese, R. *Cannabinoids in Health and Disease*; InTech: London, UK, 2016.
25. Fučak, T.; Kreft, S.; Svedružić, Ž.M.; Tavčar, E. Mechanism and kinetics of CBDA decarboxylation into CBD in hemp. *J. Plant Biochem. Biotechnol.* **2023**, *32*, 608–621. [[CrossRef](#)]
26. Ministerio de Salud. Resolución 673/2022. Available online: <https://www.boletinoficial.gob.ar/detalleAviso/primera/259987/20220329> (accessed on 16 August 2023).
27. Cascio, M.G.; Gauson, L.A.; Stevenson, L.A.; Ross, R.A.; Pertwee, R.G. Evidence that the plant cannabinoid cannabigerol is a highly potent  $\alpha$  2-adrenoceptor agonist and moderately potent 5HT 1A receptor antagonist. *Br. J. Pharmacol.* **2010**, *159*, 129–141. [[CrossRef](#)] [[PubMed](#)]
28. Food and Drug Administration. EPIDIOLEX®USPI. Highlights of Prescribing Information: EPIDIOLEX®(Cannabidiol) Oral Solution. Available online: [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2020/210365s005s006s007lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210365s005s006s007lbl.pdf) (accessed on 16 August 2023).
29. Ministerio de Salud. Resolución Directoral N.º 140-2012-DIGEMID-DG-MINSA Listado de Referencias Bibliográficas que Sustentan la Seguridad de Uso y Uso Tradicional de Recursos Naturales o Sus Asociaciones del Ministerio de Salud del Perú. Available online: <https://www.gob.pe/institucion/minsa/normas-legales/241178-140-2012-digemid-dg-minsa> (accessed on 16 August 2023).
30. Von Elm, E.; Altman, D.G.; Egger, M.; Pocock, S.J.; Gøtzsche, P.C.; Vandenbroucke, J.P. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies. *J. Clin. Epidemiol.* **2008**, *61*, 344–349. [[CrossRef](#)] [[PubMed](#)]
31. Lazarjani, M.P.; Young, O.; Kebede, L.; Seyfoddin, A. Processing and extraction methods of medicinal cannabis: A narrative review. *J. Cannabis Res.* **2021**, *3*, 32. [[CrossRef](#)] [[PubMed](#)]

32. Chasiotis, V.; Tsakirakis, A.; Termentzi, A.; Machera, K.; Filios, A. Drying and quality characteristics of *Cannabis sativa* L. inflorescences under constant and time-varying convective drying temperature schemes. *Therm. Sci. Eng. Prog.* **2022**, *28*, 101076. [[CrossRef](#)]
33. United Nations Office on Drugs and Crime. *World Drug Report 2023*; UNDOC: Geneva, Switzerland, 2023.
34. Fernández, S.; Castro, R.; López-Radcenco, A.; Rodríguez, P.; Carrera, I.; García-Carnelli, C.; Moyna, G. Beyond cannabinoids: Application of NMR-based metabolomics for the assessment of *Cannabis sativa* L. crop health. *Front. Plant Sci.* **2023**, *14*, 1025932. [[CrossRef](#)] [[PubMed](#)]
35. Editorial. El 70% de Pacientes de Cannabis no Compra su Medicina en Farmacias y Boticas Debido a Trabas. La República. Available online: <https://larepublica.pe/sociedad/2022/05/26/cannabis-el-70-de-pacientes-no-compra-su-medicina-en-farmacias-o-boticas-autorizadas-debido-a-trabas-marihuana-minsa-atmp> (accessed on 16 August 2023).
36. Kane, M. Peru Destroys Massive Marijuana Crop, Pointing to Possible Rise in Cultivation. InSight Crime. Available online: <https://insightcrime.org/news/brief/peru-destroys-massive-marijuana-crop-pointing-to-possible-rise-in-cultivation/> (accessed on 16 August 2023).
37. Wong-Salgado, P.; Moya-Salazar, M.M.; Goicochea-Palomino, E.; Moya-Salazar, J. The current context of a cannabis regulatory change: Analysis of a Peruvian course. *Rev. Cub. Med. Mil.* **2023**, *52*, e02302434. Available online: <https://revmedmilitar.sld.cu/index.php/mil/article/view/2434> (accessed on 10 July 2023).

**Disclaimer/Publisher's Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.